Navigation Links
OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Date:8/3/2009

BOTHELL, WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company will announce second quarter financial results on Thursday, August 6, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. EDT that afternoon to discuss quarterly results.

The webcast can be accessed on the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7912 (U.S. Canada) or 719-325-4897 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
2. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
3. OncoGenex Pharmaceuticals Added to Russell Indexes
4. OncoGenex Pharmaceuticals Files Shelf Registration Statement
5. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
8. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
9. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
10. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
11. OncoGenex Reports First Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., Dec. 1 Reportlinker.com announce...n its catalogue: ,, Chromium - Global Market ...94/Chromium---Global-Market-Trends.html ,, Wor... by stainless steel, while growth in aerospace and...for growth of chromium metal. Environmental constr...
(Date:12/1/2009)..., Dec. 1 Reportlinker.com announce...n its catalogue: ,, Emerging Clinical Trial Lo...changing healthcare and regulatory environment ,...-Clinical-Trial-Locations---Eastern-Europe-Market-...y-environment.html ,, Over the last decade pha...
(Date:12/1/2009)...GE, Mass., Dec. 1 To address the e...promote its potential, a group of individuals and ... Biology Industry Association (SynBIA) in Cambridg...ation is to provide a forum for individuals and co...dress its opportunities and its challenges, and ad...
(Date:12/1/2009)... Dec. 1 /PRNewswire-Asia/ -- Shanghai ChemPartner,...ing China-based Contract Research,Organization (CR...oitte,Technology Fast 50 China, ranking 3rd on the...n China. The award is a testament to ChemPartner,s...o 2008. , The results of the 2009 Deloitt...
Breaking Biology Technology:Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3
...h,Corporation (NYSE: SGP ) today announced the su...action with Virbac, S.A. to divest animal health,p...s were requested by the,European Commission as par... of Organon BioSciences N.V., In Europe, Virbac a...sulphonamide franchises of Intervet/Schering-Ploug...
...drenex,Pharmaceuticals set it sights on building a...," the small Durham company has signed its second ...elop a new compound for,hypertension and other pot...he hormone that triggers the "fight or,flight" rea...cientists,recognized this hormone, and its counter...
...y,Innovation Network (DVIN) announced today the aw...Wistar Institute will receive $89,000 to support t...gram, a two-year workforce,development program in ...rogram provides Community College of Philadelphia ... training while preparing for,careers as Biomedica...
Other Biology Technology:Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products 2Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications 2Delaware Valley Innovation Network Awards First Innovation Investment Grant to the Wistar Institute 2Delaware Valley Innovation Network Awards First Innovation Investment Grant to the Wistar Institute 3
(Date:12/2/2009)...-American adolescents exposed to cigarette smoking...abit themselves, and this may be part of the accul...n, according to new study findings. , "Our study...ates and highlights the global implementation of t...on Tobacco Control, which includes guidelines for ...
(Date:12/2/2009)...9572; A Smoky Mountain forest,s woodland herb popu...ow forest understories recover from logging, accor...avy logging in portions of the forest nearly 80 ye...e secondary forest floor was similar to that of un...nt professor of forestry and natural resources, sa...
(Date:12/2/2009)...sed of undergraduate students from Stevens Institu...nal poster contest hosted by the International Soc...e annual contest highlights the research conducted...PE Annual Meeting in San Diego, Calif. , The win...ciate Ligament Tensioning Device," was presented b...
Breaking Biology News(10 mins):Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Study finds logging effects vary based on a forest's history, climate 2Richard T Crowder Joins Neogens Board of Directors 14944 1Richard T Crowder Joins Neogens Board of Directors 14944 2Lexicon to Present Positive Top Line Phase 2 Results for LX1031 in Non Constipating Irritable Bowel Syndrome at GASTRO 2009 6466 1Lexicon to Present Positive Top Line Phase 2 Results for LX1031 in Non Constipating Irritable Bowel Syndrome at GASTRO 2009 6466 2Lexicon to Present Positive Top Line Phase 2 Results for LX1031 in Non Constipating Irritable Bowel Syndrome at GASTRO 2009 6466 3Reported Use of AMAGs Feraheme 28ferumoxytol 29 Continues To Be Low But a Number of Nephrologists Are On the Verge of Use 6464 1Reported Use of AMAGs Feraheme 28ferumoxytol 29 Continues To Be Low But a Number of Nephrologists Are On the Verge of Use 6464 2
...in a western or southeastern state can pump as muc...s as the state,s entire motor vehicle traffic does...by scientists at the National Center for Atmospher...at Boulder. , The paper, "Estimates of CO2 from f... management," is being published online today in t...
... 1st and November 15th issues of Biophysical Journ...available online. Topics of interest include volt...synthetic drug design, the absence of large lipid ...porter dimmer. , Volume 93, Issue 9, November 1... channel in a Membrane Environment , Vishwanath Jo...
...des on a pair of plastic 3-D glasses and an uneart...t of a sci-fi horror flick -- seems to leap out of...his is no movie director,s fantasy. The horror ima...adly anthrax bacteria -- specifically one of its p...einberg School of Medicine are mapping parts of th...
Other Biology News:US fires release large amounts of carbon dioxide 2US fires release large amounts of carbon dioxide 3Media highlights in the November issues of Biophysical Journal 2Media highlights in the November issues of Biophysical Journal 3Northwestern to expose most deadly infectious diseases in 3-D 2Northwestern to expose most deadly infectious diseases in 3-D 3Northwestern to expose most deadly infectious diseases in 3-D 4
Mouse Anti-Hamartin Monoclonal Antibody, Unconjugated, Clone 1B2 from Cell Signaling Technology
Blank Calibration Particles, 3.0-3.4 mu m from BD Biosciences Pharmingen
Rabbit Anti-Human SYT16 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Anti-IL-12 / IL-23 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone C17.8 from eBioscience
Biology Products: